Insulin Delivery
Lilly to integrate Dexcom CGM into personalized diabetes devices
Eli Lilly and Dexcom announced a global commercialization agreement to integrate DexCom’s continuous glucose monitoring devices into a personalized diabetes management system currently in development to advance the treatment of diabetes, according to a press release from the companies.
FDA authorizes marketing of first interoperable insulin dosing controller
The FDA on Friday authorized marketing of the Tandem Diabetes Care Control-IQ interoperable, automated insulin dosing algorithm, the first dosing controller that can be used with other interoperable diabetes devices, allowing people with diabetes to create a customizable automated insulin delivery system, according to an agency press release.
As diabetes technologies advance, matching patients to the ‘right’ device challenges providers
Diabetes devices such as sensors, insulin pumps and continuous glucose monitors continue to improve, offering people with diabetes more opportunities for connected care. As a result, adoption of these technologies is gradually rising. Approximately 30% to 40% of people with type 1 diabetes and an increasing number of people with insulin-dependent type 2 diabetes are using pump and sensor technology, according to a 2018 review published in Diabetes Care. Another recent study shows CGM can be cost-effective for adults with diabetes when compared with the daily use of test strips and improves overall blood glucose levels while reducing hypoglycemia.
Diabetes technology news you may have missed
Diabetes care provider helps others adopt new technology
HOUSTON — Diabetes care is not a static endeavor. Health care providers and patients alike are inundated with new technology and information about how to best care for diabetes. For Jennifer A. LeBlanc, BSN, RN, CDE, director of professional education and care delivery at the Joslin Diabetes Center of Harvard Medical School in Boston, finding ways to simplify this process is crucial.